Ketamine Metabolite (2 R,6 R)-Hydroxynorketamine Interacts with μ and κ Opioid Receptors
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
values congruous with our simulations. Overall, our findings are consistent with opioid pathway involvement in ketamine function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Sigmoidal dose–response inhibition curves from [35S]GTPγS assays, including standard deviations. Increasing concentrations of HNK depress activation in both MOR and KOR, suggesting an inverse agonist effect. This is attenuated by pretreatment with naltrexone in both MOR and KOR.](https://figures.cochat.ai/paper-figures/93ef94d2282a46cd9d55bd3e7ce349f7/ketamine-metabolite-2-i-r-i-6-i-r-i-hydroxynorketamine-interacts-with-and-opioid-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The effect of (2R,6R)-HNK was blocked by pretreatment with the opioid receptor antagonist naltrexone”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Joseph et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is possible that inverse agonism of μ and κ-opioid receptors may help to restrict the potential for abuse of (2R,6R)-HNK similar to how naltrexone helps prevent relapse in opioid and alcohol use disorders, however this assertion requires further research”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Joseph et al., 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“computational analyses of the predicted interaction between ketamine and its metabolites to the μ and κ-opioid receptor suggested that (2R,6R)-HNK interacted with the orthosteric binding pockets at high affinity (Joseph et al., 2021).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Joseph et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“This study also used G-protein recruitment assays to conclude that (2R,6R)-HNK acts as an inverse agonist, with IC50 values of 0.56 nM and 2.1 x 10−5 nM for the μ and κ-opioid receptor, respectively.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Joseph et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“whereas (2R,6R)-HNK may be an inverse agonist at μ and κ-opioid receptors within antidepressant relevant concentrations, though these findings require replication.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Joseph et al., 2021
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trott, O., & Olson, A. J. (2010) · Journal of Computational Chemistry · doi:10.1002/jcc.21334 · Cited by 38,412
Scalable molecular dynamics with NAMD
Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., & Schulten, K. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20289 · Cited by 16,914 · cited 1×
“All simulations were conducted with NAMD 2.12 or 2.13 molecular dynamics software, 53 using GPUs where possible.”
InfluentialCHARMM‐GUI: A web‐based graphical user interface for CHARMM
Jo, S., Kim, T., Iyer, V. G., & Im, W. (2008) · Journal of Computational Chemistry · doi:10.1002/jcc.20945 · Cited by 9,284
Best, R. B., Zhu, X., Shim, J., Lopes, P. E. M., Mittal, J., Feig, M., & MacKerell, A. D. (2012) · Journal of Chemical Theory and Computation · doi:10.1021/ct300400x · Cited by 4,532
Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types
Klauda, J. B., Venable, R. M., Freites, J. A., O’Connor, J. W., Tobias, D. J., Mondragon-Ramirez, C., Vorobyov, I., MacKerell, A. D., & Pastor, R. W. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp101759q · Cited by 4,501
Crystal structure of the β2 adrenergic receptor–Gs protein complex
Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., et al. (2011) · Nature · doi:10.1038/nature10361 · Cited by 3,009
Automation of the CHARMM General Force Field (CGenFF) I: Bond Perception and Atom Typing
Vanommeslaeghe, K., & MacKerell, A. D. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300363c · Cited by 2,169
ESTIMATION OF PURE-COMPONENT PROPERTIES FROM GROUP-CONTRIBUTIONS
JOBACK, K. G., & REID, R. C. (1987) · Chemical Engineering Communications · doi:10.1080/00986448708960487 · Cited by 1,965
Vanommeslaeghe, K., Raman, E. P., & MacKerell, A. D. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci3003649 · Cited by 1,750
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Research works printed but not linked: 1
- Cohen M. L., 1974, J. Pharmacol. Exp. Ther., 189, 351
Cited by
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
Bonaventura, J., Gomez, J. L., Carlton, M. L., Lam, S., Sánchez‐Soto, M., Morris, P. J., Moaddel, R., Kang, H. J., Zanos, P., Gould, T. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01673-w · Cited by 49
Jiang, C. S., Dileone, R., Pittenger, C., & Duman, R. S. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02796-0 · Cited by 50
Alchemical Free Energy Calculations on Membrane-Associated Proteins
Papadourakis, M., Sinenka, H., Matricon, P. G., Hénin, J., Brannigan, G. H., Pérez‐Benito, L., Pande, V., van Vlijmen, H., de Graaf, C., Deflorian, F., et al. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00365 · Cited by 35
Self-citationWulf, H. A., Browne, C. A., Zarate, C. A., & Lucki, I. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06118-4 · Cited by 26
Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect
Bottemanne, H., Berkovitch, L., Gauld, C., Balcerac, A., Schmidt, L., Mouchabac, S., & Fossati, P. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105410 · Cited by 33
“…D-aspartate receptor (NMDAr) antagonist but it can also bind to the serotonin transporter (Spies et al., 2018) as well as μ and κ opioid receptors (Joseph et al., 2021), HCN1 (hyperpolarization-activated cyclic nucleotide-gated) receptors, and cholinergic receptors (Sleigh et al., 2014;…”
Ketamine and Major Ketamine Metabolites Function as Allosteric Modulators of Opioid Receptors
Gomes, I., Gupta, A., Margolis, E. B., Fricker, L. D., & Devi, L. A. (2024) · Molecular Pharmacology · doi:10.1124/molpharm.124.000947 · Cited by 30
Adžić, M., Lukić, I., Mitić, M., Glavonic, E., Dragicevic-Curic, N., & Ivković, S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121803 · Cited by 24
New investigational agents for the treatment of major depressive disorder
Pochwat, B., Krupa, A. J., Siwek, M., & Szewczyk, B. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2113376 · Cited by 23
Ribeiro, F. C., Cozachenco, D., Argyrousi, E. K., Staniszewski, A., Wiebe, S. A., Calixtro, J. D., Soares‐Neto, R. L., Al‐Chami, A., Sayegh, F. E., Bermudez, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14034 · Cited by 19
Contribution of the Opioid System to the Antidepressant Effects of Fluoxetine
Arias, E. C., Nguyen, P. T., Kass, M. D., Jee, H. J., Nautiyal, K. M., Magalong, V. M., Coie, L. A., Andreu, V., Gergues, M. M., Khalil, H., et al. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.05.030 · Cited by 20
Michael, A., Onisiforou, A., Georgiou, P., Koumas, M., Powels, C. F., Mammadov, E., Georgiou, A. N., & Zanos, P. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70018 · Cited by 15
“…at physiologically relevant concentrations (Bonaventura et al., 2022; Joseph et al., 2021), its inverse agonist properties at these two receptors (Joseph et al., 2021) suggest that it may attenuate basal opioid receptor activity, which is often dysregulated in opioid dependence and…”
Pardossi, S., Fagiolini, A. M., Scheggi, S., & Cuomo, A. (2024) · Children · doi:10.3390/children11070801 · Cited by 23
Endogenous opiates and behavior: 2021
Bodnar, R. J. (2023) · Peptides · doi:10.1016/j.peptides.2023.171004 · Cited by 12
The effects of (2R,6R)-hydroxynorketamine on oxycodone withdrawal and reinstatement
Drinkuth, C. R., Lehane, M. J., & Sartor, G. C. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.110987 · Cited by 10
Stopera, C. J., Bartlett, M. J., Liu, C., Esqueda, A., Parmar, R., Heien, M. L., Sherman, S. J., & Falk, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110047 · Cited by 13
“…but it also has a high binding affinity for opioid receptors (Finck and Ngai, 1982; Smith et al., 1987; Hirota et al., 1999); and its additional mechanism as a known positive allosteric modulator (PAM) of the MOR and KOR (Joseph et al., 2021; Bonaventura et al., 2021; Levinstein et al., 2023).”
BackgroundInfluentialMechanism-guided identification of antidepressant G protein-coupled receptor drug targets
Munguba, H., Arefin, A., Hasegawa, R., Posa, L., Romano, G. R., Peddada, T., Donatelle, A., Singh, A., Gutzeit, V. A., Vijay, A., et al. (2026) · Cell · doi:10.1016/j.cell.2026.04.006 · Cited by 12
Zheng, Z., Kyzer, J. L., Worob, A., & Wenthur, C. J. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00498 · Cited by 8
Antidepressants and the endogenous opioid system
Fricker, L. D., Osman, A., Gupta, A., Gomes, I., & Devi, L. A. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117392 · Cited by 12
Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies
Pulido-Saavedra, A., Oliva, H. N. P., Prudente, T. P., Kitaneh, R., Nunes, E. J., Fogg, C., Funaro, M. C., Weleff, J., Nia, A. B., & Angarita, G. A. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05519-2 · Cited by 12
Efficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen, W., Zhao, W., Xia, X., Duan, X., Zhang, L., Lin, D., Qi, Z., Wang, S., Gao, M., Liu, C., et al. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173773 · Cited by 9
Yen, Y., Tseng, S.-H., Huang, D., Tsai, Y.-S., Lee, L.-W., Chen, P., Liu, Y.-L., & Chyueh, S. (2022) · Forensic Science International · doi:10.1016/j.forsciint.2022.111241 · Cited by 6
Qian, J.-J., Zhang, F., Chen, W., Zhu, B.-L., Jin, F.-Y., Shen, J., Jiang, B., & Fan, H. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110632 · Cited by 2
Zhang, G., Pan, T., Zhang, J., Gu, Y., Zhu, Z., Zhong, X., Wang, J., Li, Y., Gao, X., Wang, J., et al. (2026) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2026.118730 · Cited by 2
Mechanism of antidepressant action of ketamine and differences between its two enantiomers
Zhan, J., Zhang, Y., Tian, H., Zhu, X., Guo, M., Qiu, Z., & Xia, Z. (2025) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2025.06.001 · Cited by 1
“179 182 The use of metabolic inhibitors of R ketamine revealed that (2 R,6 R)-HNK was not essential for the antidepressant effects of R ketamine.”
Disruption of psychostimulant-associated memories by single, low dose ketamine in rats
Gonzalez, A. E., Ramos, J. D., Anderson, Z., Sewell, C. M., Modaberi, S., Hentges, S. T., Brown, T. E., & Sorg, B. A. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.110912 · Cited by 1
“…lack of lever-pressing during the memory retrieval session in roughly half of the animals trained on fentanyl may have been related to the ability of ketamine or its metabolites to activate μ-opioid receptors ( Bonaventura et al., 2021; Joseph et al., 2021) and dampen activity levels on this day.”
Yang, S., Wang, L. J., Sun, Y., Ma, X. Y., Rong, Y., Fong, T. H., Li, T., Deng, D., Li, X.-X., Zhang, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.31.727553
Chen, Y., Yang, S., Rong, Y., Ye, Y., Chen, T., Yan, P., Cai, X., laijh1011@mail.xjtu.edu.cn, & Zhou, Q. (2026) · Research Square · doi:10.21203/rs.3.rs-10989533/v1
Metadata
- Authors
- Joseph, T. T., Bu, W., Lin, W., Zoubak, L., Yeliseev, A., Liu, R., Eckenhoff, R. G., & Brannigan, G.
- Affiliations
- University of Pennsylvania (US)
- Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States
- National Institutes of Health (US)
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- Joseph, Thomas T.
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-04-27
- Volume
- 12
- Issue
- 9
- Pages
- 1487-1497
- ISSN
- 1948-7193 (ISSN-L)
- PMC
- PMC8154314
- OpenAlex
- W3157868786
- Cited by
- 28
- References
- 60
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 5 · 2021: 2
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- ACS Chemical Neuroscience (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Foundation for Anesthesia Education and Research
- National Institute on Alcohol Abuse and Alcoholism
- National Institute of General Medical Sciences (K08GM139031, R01GM111421, T32GM112596)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- ketamine metabolites, (2R,6R)-hydroxynorketamine, mu-opioid receptor, kappa opioid receptor, opioid receptor interaction, molecular docking
- MeSH terms
- Antidepressive Agents, Depression, Ketamine, Receptors, Opioid, kappa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.